Skip to main content

Table 1 Baseline characteristics in diabetic patients with NAFLD

From: Effect of omega-3 supplementation on cardiometabolic indices in diabetic patients with non-alcoholic fatty liver disease: a randomized controlled trial

 

Omega-3 (n = 30)

Placebo (n = 30)

Age*, y

48.6 ± 7.6

48.8 ± 8.7

Gender*

 Male, n (%)

9 (30)

6 (20)

 Female, n (%)

21 (70)

24 (80)

Energy intake, kcal/d

1585.1 ± 572.8

1200.2 ± 295.5

MET, (h/d)

28.1 ± 4.2

27.7 ± 3.9

Height*, cm

160.4 ± 8.9

160.5 ± 8.2

Weight*, kg

78.0 ± 10.5

77.1 ± 12.5

BMI*, kg/m2

30.2 ± 3.6

29.8 ± 4.2

WC*, cm

106.7 ± 9.1

104.2 ± 9.8

HDL-c*, mg/dL

45.3 ± 8.9

46.5 ± 8.03

LDL-c*, mg/dL

95.9 ± 30.0

92.2 ± 22.2

TG*, mg/dL

151.6 ± 57.5

138.4 ± 51.8

TC*, mg/dL

166.0 ± 41.1

159.9 ± 29.3

AIP*

0.49 ± 0.22

0.44 ± 0.19

Castelli risk index I*

3.63 ± 0.9

3.41 ± 0.7

Castelli risk index II*

2.11 ± 0.6

1.97 ± 0.5

AC*

2.63 ± 0.9

2.41 ± 0.7

  1. P values are computed by independent t-test and data are expressed as mean ± standard deviation (SD), while for Gender is computed by chi-square test and data are expressed as number (percent)
  2. *: No significant difference was found between two groups at the baseline, except for energy intake (P = 0.002)
  3. NAFLD Non-alcoholic fatty liver disease, MET-h Metabolic equivalent task, BMI Body mass index, WC Waist circumference, HDL-c High density lipoprotein-cholesterol, TG Triglyceride, TC Total cholesterol, AIP Atherogenic index of plasma, AC Atherogenic coefficient